AIGEN INVESTMENT MANAGEMENT, LP - INTRA CELLULAR THERAPIES INC ownership

INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 290 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2023. The put-call ratio across all filers is 1.03 and the average weighting 0.2%.

Quarter-by-quarter ownership
AIGEN INVESTMENT MANAGEMENT, LP ownership history of INTRA CELLULAR THERAPIES INC
ValueSharesWeighting
Q2 2023$900,410
+97.7%
14,220
+69.1%
0.13%
+111.1%
Q1 2023$455,402
-72.5%
8,410
-87.0%
0.06%
-70.3%
Q3 2020$1,658,000
+3943.9%
64,625
+5289.9%
0.21%
+2928.6%
Q4 2019$41,0001,1990.01%
Other shareholders
INTRA CELLULAR THERAPIES INC shareholders Q3 2023
NameSharesValueWeighting ↓
Ally Bridge Group (NY) LLC 175,000$9,115,75010.70%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 317,856$16,547,5835.57%
Deep Track Capital, LP 2,600,000$135,434,0005.23%
SUVRETTA CAPITAL MANAGEMENT, LLC 1,369,849$71,355,4343.86%
SILVERARC CAPITAL MANAGEMENT, LLC 208,730$10,872,7463.30%
DCF Advisers, LLC 107,157$5,581,8083.04%
Bellevue Group AG 3,170,250$165,138,3232.66%
Vahanian & Associates Financial Planning Inc. 15,217$792,6542.55%
Iron Triangle Partners LP 330,549$17,218,2972.52%
TANG CAPITAL MANAGEMENT LLC 300,000$15,627,0002.20%
View complete list of INTRA CELLULAR THERAPIES INC shareholders